SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, ...

VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDPApproval based on ADHERE clinical trial, the ...

A groundbreaking injectable medication has demonstrated remarkable effectiveness in reducing cholesterol levels, potentially ...

Developed by Gilead Sciences and marketed as Yeztugo for prevention (Sunlenca for treatment), this innovative subcutaneous ...

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...

The FDA on Wednesday approved a highly effective long-acting shot for HIV prevention that is administered just twice per year ...

CSL Behring’s Andembry is now approved as a subcutaneous, self-injection for hereditary angioedema (HAE) patients ages 12 and older and will be available by the end of June 2025.

Individuals at risk for sexually acquired HIV have a new injectable option for preexposure prophylaxis (PrEP) with the US ...

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse ...